Botox 200 unit vials
Ended Awarded
- Contract number
- SPE2DR26FJXE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,281
Award facts
- Contract value 100% obligated
- $5,281.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $5,281.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 200 unit vials. The order, awarded on November 14, 2025, with an ultimate completion date of December 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's newly awarded Indefinite Delivery Contract (IDC) designated SPE2DR under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to consolidate pharmaceutical sourcing for Department of Defense healthcare operations.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499.9 million with a completion date of December 31, 2036, comprising a 30-month base period and three 30-month option periods. This indefinite delivery vehicle authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's extensive product portfolio and demonstrated federal contracting experience position it as a critical supplier within the Department of Defense's global pharmaceutical supply chain, with this BOTOX delivery order representing one of numerous orders expected to be issued under the prime vendor contract to fulfill recurring medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FJXE7?
SPE2DR26FJXE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FJXE7 worth?
The government has obligated $5,281 on SPE2DR26FJXE7.
Is contract SPE2DR26FJXE7 an order under another contract?
Yes. SPE2DR26FJXE7 is a delivery order under SPE2DR25D9307, an indefinite delivery contract.
Was contract SPE2DR26FJXE7 competed?
The extent of competition for SPE2DR26FJXE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award